Management

Laura Nevola, PhD (CSO, COO, Founder)

Dr. Nevola received her degree in medicinal chemistry and Ph.D in Pharmaceutical Science from the University of Rome “Sapienza” (Italy). After her stay at the laboratory of Prof. Dr. Hamilton at Yale University (USA) she moved to the Institute for Research in Biomedicine (IRB Barcelona). She is an expert in peptidomimetics, has designed several de novo drugs and led multiple drug discovery projects.

Santiago Esteban, PhD (CEO, Founder)

Dr. Esteban got his Ph.D in chemistry at the Institute of Molecular Science (Spain) and worked at several international institutions (KIT, Groningen Institute of Biotechnology, IRB). Dr. Esteban managed IDP Pharma since its foundation, focussing on strategic growth and business development. He is an expert in hard to drug therapeutic targets i.e. IDPs.

Tim Hammond, PhD, Professor, FRCPath (VP Toxicology)

35 years of experience in pharmaceutical drug Discovery and Development. He was former Vice President of Safety Assessment in the UK for AstraZeneca, responsible for non-clinical safety development of the full oncology portfolio, including registration of Irressa and Olaparib, among others. He has extensive experience in the selection, early development and registration of modalities intended to be used in oncology. Currently he is an independent consultant.

Ella Korets-Smith Ms. MBA, MSc (CDO)

Ms. Korets-Smith is a business development executive with over 15 years of experience in the biotechnology and pharma industries. Ms. Korets-Smith has a track record of closing deals, fundraising and liquidity events. Her extensive business network extends to customers and partners in all key markets in North America and around the world.

Jordi Petit Salamó, MBA (CFO)

Mr. Petit (MBA, ESADE) has a broad experience in corporate finance, venture capital and in the financial area of startups, SMEs, multinationals and large companies. He has worked during more than 25 years in different financial directive positions (Betne, Bull Europe, KPMG, Caixa Capital Risc), including biotech companies (Oryzon Genomics).

Disse er de mest almindelige, men der er snesevis mere. Vi vil se på, hvordan de resistente bakterier kan spredes, og hvordan antibiotikaresistens spreder sig, og hvordan mina poteker det spreder sig gennem befolkningen. Hvad vi virkelig er interesseret i, er bedre at forstå den proces, der har givet anledning til den modstand, vi taler om.